Kornimate/medical-research-clean huggingface dataset:
als study determining various biomarkers and strength comparison after exercise

Conditions: Amyotrophic Lateral Sclerosis

Summary: the purpose of this study is to determine the muscle strength of a muscle in the thigh after 12 weeks of home exercise.

study participation lasts a total of three months and includes two study visits. subjects are asked to undergo strength testing, physical exams, lab draws, and muscle biopsies at each study visit. muscle biopsies are done in the quadriceps muscle. in between study visits, subjects are asked to maintain a weekly exercise regimen given to them by the study physical therapist.

Eligibility criteria:
inclusion criteria: * diagnosis of possible, probable or definite amyotrophic lateral sclerosis (als) based on the revised el-escorial criteria * presence in ipsilateral leg of either weakness in any muscle group or of active denervation by needle electromyography (emg) which is a surrogate marker of early denervation * ipsilateral quadriceps femoris strength: \>=4 * ambulatory with or without assistance * revised als functional rating scale (alsfrs-r) score \> 30 * forced expiratory vital capacity (fvc) \>50% of predicted exclusion criteria: * alsfrs-r ≤ 30 * quadriceps femoris strength \<4 * unable to walk or uses wheelchair as primary means of mobility * more than mild atrophy of quadriceps * bleeding disorder or uptake of anticoagulants * unwilling to comply with exercise and needle muscle biopsy * not a good research candidate according to the medical opinion of investigator

Keywords: als
effects of vaginal oxytocin gel on vaginal cytologic parameters in postmenopausal woman

Conditions: Vaginal Atrophy; Oxytocin Gel; Postmenopausal Women; Vaginal Maturation Index

Summary: vulvovaginal atrophy affects around 90% of postmenopausal women who may present with symptoms such as dryness, irritation, itching, burning, and dyspareunia that negatively affect the quality of life. topical estrogen is recommended for the treatment of vulvovaginal atrophy in postmenopausal women and the fda approved it. but it may increase the risk of breast and endometrial cancer. the oxytocin hormone also promotes positive social behavior, stress regulation, and female sexual arousal. many previous studies show that topical oxytocin is useful for reducing vaginal atrophy in postmenopausal women.

random and conducted on 56 postmenopausal women who meet the inclusion criteria and excluded participants that have exclusion criteria. all women provided written informed consent before data collection. 1. st visit: the vagina was assessed regarding infection and any abnormal discharge. the participants were evaluated vaginal signs of vaginal atrophy by per vaginal examination and assessed vaginal health index score. the subjective symptoms were assessed by the most bothersome score. the vaginal ph was tested with a nitrazine paper. the vaginal swab was done and the specimen was sent for a cytological test - vaginal maturation index evaluation (vmi). the participants were separated into two groups 1. oxytocin gel group and 2. placebo gel group then applied gel 1 ml. (400iu of oxytocin in oxytocin gel) per day for 8 weeks consecutively. the subjective symptoms were assessed at 2 and 4 weeks by phone. 2. nd visit: the participants were assessed the same as 1st visit that recorded vaginal health index score, subjective symptoms, vaginal ph, and vaginal maturation index evaluation.

Eligibility criteria:
inclusion criteria: * thai menopausal women aged between 50-70 years who visit rajavithi gynecology opd with informed consent with good communication in the thai language. exclusion criteria: * have acute vulvovaginitis (vaginal swab for wet smear and koh) * patients who have used hormonal replacement therapy within 12 months * patients with a history of smoking * patients who have used vaginal lubricant or moisturizer * patients with an allergic history of oxytocin or gel components * morbid obesity bmi \> 30 kg/m2 * patients who have used vitamin e supplement * patients who unable to perform per vaginal examination
study of the association between fatigue experienced by patients and the specific side effects of cart cells, during the first month after administration for non-hodgkin's lymphoma

Conditions: Fatigue Symptom; Lymphoma Non-Hodgkin; Chimeric Antigen Receptor T-cell Therapy; Adverse Events

Summary: the incidence of cancer in 2023 is estimated at 433136 cases, according to inca. haemopathies account for 12% of these new cases of cancer cases of cancer, and around two-thirds are lymphoid haemopathies, in particular lymphomas. there are many treatments available for lymphoma. however, the arrival in france in 2018 of immunotherapy treatments such as car-t cells have changed the paradigm of treatment options for certain non-hodgkin's lymphomas. in these treatments can have both short-term and long-term adverse effects and long-term adverse effects. during hospitalisation for the administration of car-t cells, acute side effects include crs and icans. there is also another complication very specific to this treatment that has been observed in patients: cytopenias. this is despite the fact that one of the symptoms frequently mentioned and felt by patients during the first month after month after treatment is fatigue. despite numerous studies on the prevalence of fatigue, healthcare professionals often underestimate this symptom. nurses, and in particular the advanced practice nurse have a crucial role to play in assessing fatigue. the eortc scale qlq-fa12 is a multidimensional scale which assesses the physical emotional and cognitive dimensions of fatigue. the theory of symptom management, which was developed in 1994 by the california college of nursing in san francisco, is a relevant framework for understanding fatigue in patients. this theory places the patient's experience at the centre of care. this holistic approach provides a detailed framework for understanding this symptom. "according to the theoretical model, measuring the symptom is an important step and characterising it is an essential element in better targeting the actions to be taken". although car-t cell therapy is innovative and allows long-term remissions, it is important to evaluate and understand how patients live with this treatment. to our knowledge, few studies have been carried out on quality of life, particularly regarding fatigue, following the first month of car-t cell administration. the research question we will address in this study is: "is there an association between the side effects of car-t cell treatment and the state of fatigue in patients receiving this treatment for non-hodgkin's lymphoma during the first month?"


Eligibility criteria:
inclusion criteria: * adult (age\> 18year old) * person hospitalised for treatment with car-t cells for non-hodgkin's lymphoma. * person able to understand and read the french language. exclusion criteria: * patient under legal protection * opposition to research

Keywords: fatigue car-t cells chimeric antigen receptor adverse events lymphoma non-hodgkin nurse practitionners
sonazoid enhanced liver cancer trial for early detection

Conditions: Hepatocellular Carcinoma; Liver Cirrhosis; Hepatitis B; Hepatitis C

Summary: the aim of this study is to prove usefulness of contrast-enhanced ultrasound (ce-us) using sonazoid (tm) in the early detection of hcc as compared with conventional b-mode ultrasound (b-mode us) for hepatitis virus related cirrhosis, who are defined as super high-risk patients for hepatocarcinogenesis,furthermore, to analyze whether early detection of hcc by ce-us has a survival benefit than that by b-mode us.


Eligibility criteria:
inclusion criteria: 1. age over 20 2. hbv or hcv related liver cirrhosis 3. no history of hcc 4. diagnosed as liver cirrhosis histologically or clinically histologically confirmed by liver biopsy confirmed by formula of diagnosing cirrhosis radiological finding finding of portal hypertension platelet\<130,000 5. inpatient or outpatient 6. patients who signed a written informed consent form exclusion criteria: 1. history of hypersensitivity to egg yolk 2. pregnant or lactating women and women who may be pregnant 3. severe liver dysfunction(ast, alt,or bil level \>10uln 4. associated with hcc 5. patients receiving interferon 6. age under 20 7. judged by investigator not to be appropriate for inclusion in this study

Keywords: sonazoid early detection hepatocellular carcinoma liver cirrhosis
the first 1,000 days program: maternal-child obesity prevention in early life

Conditions: Overweight and Obesity; Social Determinants of Health; Physical Activity; Sleep; Feeding Behavior; Diet Habit

Summary: the first 1000 days (conception to age 2) is a crucial period for the development and prevention of obesity and its adverse consequences in mother-child pairs and their families. the overall aim of the first 1000 days program is to work across early-life systems to prevent obesity, promote healthy routines and behaviors, address social determinants of health, and reduce health disparities among vulnerable children and families at community health centers in the boston, ma area. the study aims to simultaneously implement and evaluate an obesity prevention program across early life systems to reduce the prevalence of obesity risk factors within racial/ethnic minority families, close the gap in maternal-child health disparities, and assess and address social determinants of health.


Eligibility criteria:
inclusion criteria: * all pregnant women receiving prenatal care at select community health centers in the boston, ma area * all families of children aged 0-2 years receiving pediatric care at select community health centers in the boston, ma area

Keywords: overweight obesity maternal-child social determinants of health
does watching video increase the perioperative anxiety in patients undergoing third molar surgery

Conditions: Anxiety

Summary: third molar extraction is the most common surgical procedure in the field of oral and maxillofacial surgery and usually cause anxiety. although different informed consent methods have been used previously, the most effective information method that provide the optimum anxiety management is still not clear. therefore, investigators planned a clinical study to explore the effect of different information formats (verbal information with written document and verbal information with written document subsequent to watching video from internet) on peri-operative anxiety of the participants who scheduled to undergo impacted lower third molar surgery. also, investigators aimed to explore the effect internet usage before the third molar surgery on the level of anxiety.

the participants were randomly divided into two groups. the control group consisted of participants who informed verbally about the surgical procedure and the potential postoperative complications,. also, a written informed consent document was given. participants in the study group were asked to watch a video which was previously uploaded to the internet and was showed procedural details of an impacted right lower third molar extraction (with permission and written consent). participants in the study group were also informed verbally about the surgical procedure-possible postoperative complications and was given with a written informed consent document. in both groups questions of the participants were answered by the same surgeon. to evaluate anxiety; participants were asked to complete 3 questionnaires one week before the procedure when taking appointment for surgery, just after watching video or informed verbally, immediately after the procedure and one week after the procedure.

Eligibility criteria:
inclusion criteria: patients; * without systemic disease, * have indication for third molar extraction, * radiographic degree of impaction according to the classification of winter (vertical and mesio-angular) and the classification of pell and gregory 2, or 3 and b exclusion criteria: patients who; * has psychiatric illness and systemic disease, * refused to watch the video, * failed to fill out the forms for any reason, * had incomplete data and wanted to withdraw from the study, * had underwent a previous third molar surgery, * had history of anxiety attacks and/or anxiolytic treatment, * had unpleasant dental treatment experience could not cooperated,
kinesio taping in subjects with myofascial pain syndrome: a randomized controlled trial

Conditions: Myofascial Pain Syndrome

Summary: musculoskeletal dysfunction is considered as a major public health problem affecting about one third of the adult population. myofascial pain syndrome (mps) characterized by myofacial trigger points as well as fascia tenderness are thought to be the main cause of musculoskeletal dysfunction. the aim of the treatment for musculoskeletal dysfunction is to reduce pain and restore normal function. clinically, some evidence supports the application of kinesio tape in these patients. the underlying mechanism, however, is not clear. the investigators goal was to validate proposed mechanism of kinesio tape in these patients. the primary outcome are muscle stiffness, pain intensity and sensitivity.


Eligibility criteria:
inclusion criteria: * age between 20 and 60 years * shoulder or neck pain corresponding with the area covered by the upper trapezius muscle * trigger point (taut band) in the upper trapezius muscle exclusion criteria: * diagnosis of fibromyalgia syndrome * having undergone myofascial therapy within the past month before the study * history of cervical spine or shoulder surgery * previous history of a whiplash injury; * diagnosis of cervical radiculopathy or myelopathy; * taking medicine that might change the pain intensity or pain threshold, such as analgesics, sedatives, substance abuse (including alcohol, narcotics); * a cognitive impairment that would prevent them from being able to understand and/or participate fully in the intervention or the measures.

Keywords: myofascial pain syndrome taping manual therapies
efficacy and safety study of kinerase® for treatment of cutaneous facial photodamage

Conditions: Skin Roughness; Mottling; Blotchiness; Pigmentation; Fine Wrinkles

Summary: the purpose of the k.i.s.s. study is to evaluate the efficacy of kinerase® cream (kinetin 0.1%) in thai patients, on the basis of the severity and clinical signs of facial photodamage.


Eligibility criteria:
inclusion criteria: 1. male and female subjects older than 35 years of age and less than 65 years of age. 2. subjects with mild, moderate or severe facial photodamage as assessed by a 10-point scale. 3. subjects willing to sign an informed consent and adhere to all protocol requirements. exclusion criteria: 1. male and female subjects with suspected porphyria, systemic or cutaneous erythematosus lupus, or any other photosensitizing disorder or drug-induced photosensitization. 2. subjects with chronic or recurring skin disease or disorder. 3. subjects with any active infectious skin disorder (herpes simplex, molluscum contagiosum, and facial warts). 4. subjects with skin cancer of the facial tissues. 5. subjects who have received any laser/ intense pulsed light (ipl) / chemical peel in the 2 months preceding the screening visit. 6. subjects with a history of topical and/or oral isotretinoin use, 6 months prior to the screening visit. 7. subjects who have been on topical retin-a or renova in the 2 months prior to the screening visit. 8. subjects who have used topical alpha-hydroxy acid skin care products in the month preceding the screening visit. 9. subjects currently on any anti-aging products and who wish to continue use of their products. 10. subjects requiring concurrent treatment that would interfere with the study assessments. 11. pregnant or lactating female subjects.
cana/met in non-diabetic women with pcos

Conditions: Polycystic Ovary Syndrome

Summary: polycystic ovary syndrome (pcos), which is associated with hyperinsulinaemia, hyperandrogenaemia, impaired glucose metabolism and aberrant adipokines production from the adipose tissue, is a heterogeneous reproductive and endocrine disorder.currently, metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with pcos. sglt-2 inhibitor, a novel glucose-lowering medication, have been shown to have positive effects on reducing body weight, blood pressure and cardiovascular events in individuals with diabetes mellitus. however, evidences related to its management in non-diabetic pcos women are limited. hence, we want to give canangliflozin combined with metformin to women with pcos to see its effect on insulin resistance.


Eligibility criteria:
inclusion criteria: 1. female aged 18- 45 years old; 2. diagnosed criteria meet the rotterdam criteria (2003); 3. insulin resistance exclusion criteria: 1. women who are pregnant or have a pregnancy plan within six months; 2. confirmed diagnosis of diabetes. 3. congenital adrenocortical hyperplasia; 4. hyperprolactinemia; 5. hyperthyroidism or hypothyroidism; 6. combined with liver or kidney diseases; 7. abnormal liver function (≥ 3 times of the upper limit of normal range); 8. abnormal renal function (gfr\<60ml/min/1.73m2); 9. adrenal or ovarian tumors secreting androgens; 10. used metformin, glucagon-like peptide-1 receptor agonists, pioglitazone and contraceptives in the last 3 months.
healing of punch graft wounds. comparative study between marigen and oasis: a non-inferiority study

Conditions: Punch Biopsy Wounds; Healing Times

Summary: the objective is to determine, if healing of punch biopsy wounds treated with the fish skin derived marigen wound dressing is non-inferior to healing with wounds treated with pig intestines derived oasis sheet wound dressing. secondary endpoints are: incidence of erythema, pain, infection, quantitative measurements of autoantibodies at baseline and 4 weeks after start of treatment


Eligibility criteria:
inclusion criteria: * \>18 yrs * healthy individual * signature of informed consent exclusion criteria: * autoimmune disease * immunosuppressive treatment * use of addictive drugs * excessive use of alcohol * known fish allergy * known allergy to proteins with porcine origin * peripheral vascular disease * pregnant women * persons receiving anticoagulation therapy or systemic corticosteroids will be excluded.

Keywords: bandages biological dressings chronic disease collagen epithelium extracellular matrix extra cellular matrix fibroblasts granulation tissue leg ulcer middle aged prospective studies soft tissue injuries treatment outcome varicose ulcer wound healing wounds and injuries biopsy autoimmunity
cxcl9 and easix for prediction of acute graft versus host disease

Conditions: GVHD,Acute

Summary: the prediction of severe acute gvhd before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic sct. the key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.


Eligibility criteria:
inclusion criteria: * patients \>18 year old admitted for allo sct pb for malignant disease.
safety study of 177lu-anti-ed-b mabs spect imaging in patients with ed-b positive solid tumors

Conditions: Solid Tumor, Adult

Summary: this is a single arm study to evaluate the safety and biodistribution of 177lu-labeled anti-ed-b mabs spect imaging in patients with ed-b positive solid tumors.

after being fully informed about the study and potential risks, all patients giving written informed consent will be evaluated to determine eligibility for study entry. patients will receive an injection of 177lu-labeled anti-ed-b mabs and will undergo spect/ct scanning to determine uptake of 177lu-labeled anti-ed-b mabs in tumor lesions and normal tissues and organs.

Eligibility criteria:
inclusion criteria: 1. patients voluntarily signed informed consent, and be able to complete the trial according to the requirement of the scheme; 2. aged 18-75, male or female; 3. patients diagnosed with solid tumors confirmed by histopathology ; 4. patients with biopsy-proven fibronectin ed-b positive; 5. at least one measurable solid lesions has been examined by 18f-fdg pet/ct (recist1.1 standard); 6. ecog score 0\~2; 7. alt, ast shall not exceed 3 times of the normal upper limit; bun, cr not exceed 1.5 times of the normal upper limit. 8. other routine examinations are within the normal range or considered acceptable by the researchers. exclusion criteria: 1. recovery from major trauma (including surgery) within 4 weeks prior to study treatment; 2. patients with systemic or locally severe infections, or other serious coexisting diseases; 3. patients with abnormal immune function or who have recently used immunosuppressive or potentiating agents including various vaccines; 4. patients with autoimmune diseases, including rheumatoid arthritis; 5. inadequate control of arrhythmias, including atrial fibrillation; 6. uncontrolled hypertension; 7. patients with allergies or allergies to any component of the imaging agent or antibody; 8. patients who cannot undergo pet/ct imaging scan; 9. syphilis, hbv, hcv, or hiv positive subjects; 10. male and female subjects of reproductive age cannot take effective contraceptive measures; 11. pregnant or lactating women; 12. patients with a history of mental illness or related conditions; 13. other subjects considered unsuitable by researchers.
comparison of nn1250 with insulin glargine in type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in africa, asia, europe and south america. the aim of this clinical trial is to compare nn1250 (insulin degludec (ideg) with insulin glargine (iglar) in patients with type 2 diabetes. subjects treated with oral antidiabetic drug(s) (oad(s)) should continue their current oad treatment at the stable, prerandomisation dose level and dosing frequency.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus (diagnosed clinically) for at least 6 months * current treatment: oral anti-diabetic drug(s) (oad(s)) alone, basal insulin alone or the combination of oad(s) and basal insulin. allowed oads are: metformin, insulin secretagogues (sulphonylureas (su) or glinides), pioglitazone with unchanged dosing for at least 3 months prior to visit 1 * hba1c: oads only users 7.0-11.0 % (both inclusive), basal insulin with/without oads users 7.0-10.0% (both inclusive) by central laboratory analysis * body mass index (bmi) below or equal to 40.0 kg/m\^2 exclusion criteria: * cancer and medical history of cancer hereof * use within the last 3 months prior to visit 1 of: glucagon-like peptide-1(glp-1) receptor agonist (exenatide, liraglutide), rosiglitazone, dipeptidyl peptidase iv (dpp-iv) inhibitors, alpha-glucosidase-inhibitors * cardiovascular disease, within the last 6 months prior to visit 1, defined as: stroke; decompensated heart failure new york heart association (nyha) class iii or iv; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty * uncontrolled treated/untreated severe hypertension (systolic blood pressure at least 180 millimetre (mm) mercury (hg) and/or diastolic blood pressure at least 100 mmhg) * pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements * cancer and medical history of cancer hereof (except basal cell skin cancer and squamous cell skin cancer)